Serological Investigation of COVID-19 Antibodies in Armenia  

作　　者：Inessa Nazaryan Shahane Mnatsakanyan Narek Pepanyan Inessa Nazaryan;Shahane Mnatsakanyan;Narek Pepanyan(EcoSence LLC, Yerevan, Armenia)

机构地区：[1]EcoSence LLC, Yerevan, Armenia

出　　处：《Advances in Infectious Diseases》2022年第2期337-346,共10页传染病进展（英文）

摘　　要：Background: In December 2019 in Wuhan China the new coronavirus outbreak emerged and quickly spread in all parts of the world resulting to more than 500,000,000 infection cases and around 6,200,000 deaths. The global incidence of the infection is still growing as well as number of deaths. COVID-19 is a new virus, therefore not much is known about the immune response of infected organism, which is crucial not only for vaccination policy development, but also for identification of public health strategies. Aim: Current research aims to describe COVID-19 IgG levels depending on symptoms, antibiotic and antiviral medications intake history, existing chronic condition and smoking status during March-December of 2020 in Armenia. Furthermore, the study aims to help elucidate the fraction of asymptomatic or presymptomatic/sub- clinical infections in the population and understand the main risk factors for infection complication. Methodology: The cross-sectional study with convenience sampling of individuals who turned to “EcoSense” laboratories to be tested for COVID-19 IgG were examined. The NovaTec SARS-CoC-2 (COVID-19) IgG COVG940 96 Determinations ELISA test kits were used. The questionnaire was filled regarding the COVID-19 status, symptoms, exposure history, disease history, pre-existing chronic conditions, medication and vaccination history. The descriptive as well as multivariate analysis was performed. Results: Overall 1573 testing was performed 837 of subjects agreed to participate in the interview. 24.1% of participants had laboratory confirmed COVID-19 but by the time of interview were already recovered. 212 (25.3%) participants had positive IgG levels, among 126 (15.1%) participants IgG levels were in the grey zone. Out of PCR confirmed cases only 58.7% had positive IgG levels and 3.9% IgG level was in the grey zone. Headache was the most common symptom among participants (37.2% among all participants and 53.1% among participants who previously had positive COVID-19 PCR test). The second most common symptBackground: In December 2019 in Wuhan China the new coronavirus outbreak emerged and quickly spread in all parts of the world resulting to more than 500,000,000 infection cases and around 6,200,000 deaths. The global incidence of the infection is still growing as well as number of deaths. COVID-19 is a new virus, therefore not much is known about the immune response of infected organism, which is crucial not only for vaccination policy development, but also for identification of public health strategies. Aim: Current research aims to describe COVID-19 IgG levels depending on symptoms, antibiotic and antiviral medications intake history, existing chronic condition and smoking status during March-December of 2020 in Armenia. Furthermore, the study aims to help elucidate the fraction of asymptomatic or presymptomatic/sub- clinical infections in the population and understand the main risk factors for infection complication. Methodology: The cross-sectional study with convenience sampling of individuals who turned to “EcoSense” laboratories to be tested for COVID-19 IgG were examined. The NovaTec SARS-CoC-2 (COVID-19) IgG COVG940 96 Determinations ELISA test kits were used. The questionnaire was filled regarding the COVID-19 status, symptoms, exposure history, disease history, pre-existing chronic conditions, medication and vaccination history. The descriptive as well as multivariate analysis was performed. Results: Overall 1573 testing was performed 837 of subjects agreed to participate in the interview. 24.1% of participants had laboratory confirmed COVID-19 but by the time of interview were already recovered. 212 (25.3%) participants had positive IgG levels, among 126 (15.1%) participants IgG levels were in the grey zone. Out of PCR confirmed cases only 58.7% had positive IgG levels and 3.9% IgG level was in the grey zone. Headache was the most common symptom among participants (37.2% among all participants and 53.1% among participants who previously had positive COVID-19 PCR test). The second most common sympt

关 键 词：CORONAVIRUS IGG IMMUNITY SEROPREVALENCE 

分 类 号：R73[医药卫生—肿瘤]